Prostate cancer: Active surveillance for low-risk disease: who will benefit most?

Comment

Nick Warde. Nat Rev Urol. 2011 Feb.

. 2011 Feb;8(2):60.

doi: 10.1038/nrurol.2010.243.

No abstract available

Comment on

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance.
San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC. San Francisco IF, et al. J Urol. 2011 Feb;185(2):471-6. doi: 10.1016/j.juro.2010.09.115. Epub 2010 Dec 17. J Urol. 2011. PMID: 21167525
Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer.
Adamy A, Yee DS, Matsushita K, Maschino A, Cronin A, Vickers A, Guillonneau B, Scardino PT, Eastham JA. Adamy A, et al. J Urol. 2011 Feb;185(2):477-82. doi: 10.1016/j.juro.2010.09.095. Epub 2010 Dec 17. J Urol. 2011. PMID: 21167529 Free PMC article.